What are the NCCN guidelines on the treatment of metastatic thyroid cancer?

Updated: Jun 24, 2020
  • Print


NCCN recommendations for treatment of recurrent or metastatic thyroid disease include external beam radiation therapy (EBRT). [5]  Systemic therapy can be considered for tumors with all the following characteristics:

  • Not resectable
  • Not responsive to radioiodine ( 131I) therapy
  • Not amenable to EBRT
  • Showing significant disease progression

Oral kinase inhibitors (eg, vandetanib) are associated with longer progression-free survival but are not curative; side effects that may have a significant effect on quality of life should be considered. Kinase inhibitor therapy may not be appropriate for a symptomatic patients with indolent disease progression.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!